FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wells Messersmith

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Living Beings

Physiology

Co-author Network

Publications

TOP 3
Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Manon Buijs; Amanda L Blackford; Ihab R Kamel; Wells A Messersmith; Mary Mulcahy; Timothy M Pawlik; Diane K Reyes; Riad Salem; Colin D Weekes; Jean-Francois H Geschwind
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
A Dasari; S Diab; H A Drabkin; Thomas W Flaig; Lia Gore; Antonio Jimeno; Karl D Lewis; Wells A Messersmith; C D Weekes; D Ross Camidge
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wells Messersmith (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Investigational new drugs 2013;31(2):345-54.
2013: Manon Buijs; Amanda L Blackford; Ihab R Kamel; Wells A Messersmith; Mary Mulcahy; Timothy M Pawlik; Diane K Reyes; Riad Salem; Colin D Weekes; Jean-Francois H Geschwind
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Cancer 2013;119(5):1042-9.
2013: A Dasari; S Diab; H A Drabkin; Thomas W Flaig; Lia Gore; Antonio Jimeno; Karl D Lewis; Wells A Messersmith; C D Weekes; D Ross Camidge
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Investigational new drugs 2013;31(1):115-25.
2013: Todd M Pitts; Heather M Selby; Anna Spreafico; Aik Choon Tan; John J Tentler; Marileila Varella-Garcia; John Arcaroli; Erica L Bradshaw-Pierce; Blair C Britt; Maria I Kachaeva; Gillian N Kulikowski; Kelly L McPhillips; Wells A Messersmith; Brion W Murray; S Gail Eckhardt
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.
Frontiers in pharmacology 2013;4():35.
2012: John Arcaroli; Arvind Dasari; Charles Erlichman; Nathan R Foster; Manuel Hidalgo; Martine McManus; Sujatha Nallapareddy; Joel Picus; Rebecca Powell; Kevin Quackenbush; Aik Choon Tan; John Wright; Wells A Messersmith
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Cancer medicine 2012;1(2):207-17.
2012: Colin D Weekes; Lora A Wilson; Robert A Winn; Wells A Messersmith; Belen Rubio-Viqueira; Dongweon Song; John Arcaroli; George Cusatis; Elizabeth Garrett-Mayer; Manuel Hidalgo
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Neoplasia (New York, N.Y.) 2012;14(8):690-701.
2012: Gerald S Falchook; Johanna C Bendell; Howard A Burris; Douglas J DeMarini; Keith Flaherty; Rene Gonzalez; Michael S Gordon; Jeffrey R Infante; Kevin B Kim; Razelle Kurzrock; Ngocdiep T Le; Peter F Lebowitz; Karl D Lewis; Wells A Messersmith; Christopher Moy; Peter J O'Dwyer; Vijay G R Peddareddigari; Lori T Roadcap; Peng Sun; Stephen A Szabo; Nicholas J Vogelzang; Leslie A Fecher
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
The lancet oncology 2012;13(8):782-9.
2012: Jeffrey R Infante; Razelle Kurzrock; Ngocdiep T Le; Shannon R Morris; Sujatha Nallapareddy; Vijay G R Peddareddigari; Yanmei Xu; Carlos Becerra; Johanna C Bendell; Howard A Burris; Donna S Cox; Douglas J DeMarini; Gail Eckhardt; Gerald S Falchook; Leslie A Fecher; Keith Flaherty; Michael S Gordon; Lowell Hart; Wells A Messersmith
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
The lancet oncology 2012;13(8):773-81.
2012: David S Hong; Daniel W Bowles; S Gail Eckhardt; Gerald S Falchook; Goldy C George; Diana F Hausman; Roy S Herbst; Kevin Klucher; Razelle Kurzrock; Wells A Messersmith; Cindy L O'Bryant; Scott Peterson; Alex C H Vo; Antonio Jimeno
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(15):4173-82.
2012: S Leong; X Lin; Wells A Messersmith; J Spratlin; D Ross Camidge; E Chan; E Chow Maneval; S Diab; S Gail Eckhardt; R Khosravan; A C Lockhart
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;70(1):65-74.
2012: Anthony W Tolcher; Ka Wang; Zhi-Xin Xu; John F Boylan; Arvind Dasari; Mark DeMario; Jonathan Deutsch; Gerald S Falchook; Darlene G Gibbon; Astrid Koehler; Razelle Kurzrock; Eunice L Kwak; Wells A Messersmith; Steven A Middleton; Stanislaw M Mikulski; Kyriakos P Papadopoulos; Amita Patnaik; Geoffrey I Shapiro; James Song; Jennifer J Wheler
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(19):2348-53.
2012: John Arcaroli; Arvind Dasari; Dexiang Gao; Martine McManus; Todd M Pitts; Rebecca W Powell; Kevin S Quackenbush; Anna Spreafico; Aik Choon Tan; Basel M Touban; Marileila Varella-Garcia; Wells A Messersmith
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
Molecular oncology 2012;6(3):370-81.
2012: John J Tentler; Colin D Weekes; John Arcaroli; Antonio Jimeno; Stephen Leong; Wells A Messersmith; Todd M Pitts; Aik Choon Tan; S Gail Eckhardt
Patient-derived tumour xenografts as models for oncology drug development.
Nature reviews. Clinical oncology 2012;9(6):338-50.
2012: John Arcaroli; Lynne Bemis; Arvind Dasari; S Gail Eckhardt; Todd M Pitts; Rebecca W Powell; Kevin S Quackenbush; Jaclyn M Reinemann; Anna Spreafico; Aik Choon Tan; Basel M Touban; Marileila Varella-Garcia; Wells A Messersmith
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2704-14.
2012: Wen Wee Ma; Manoj Maniar; Wells A Messersmith; Chen Ren; Colin D Weekes; Amy Whitworth; Francois Wilhelm; Alex A. Adjei; Grace K Dy; S Gail Eckhardt; Antonio Jimeno
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(7):2048-55.
2012: Adil I Daud; Barbara J Gitlitz; Philip J Gold; Poe-Hirr Hsyu; Smitha S Krishnamurthi; Eric Leip; Richat Abbas; Shefali Agarwal; Nathalie Bardy-Bouxin; Mitesh J Borad; Elena G Chiorean; Mansoor N Saleh; Gregory M Springett; Kathleen Turnbull; Charles Zacharchuk; Wells A Messersmith
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1092-100.
2011: Eamon Berge; Chris Thompson; Wells A Messersmith
Development of novel targeted agents in the treatment of metastatic colorectal cancer.
Clinical colorectal cancer 2011;10(4):266-78.
2011: Colin D Weekes; Sharyn D Baker; Ross C Donehower; Manuel Hidalgo; Antonio Jimeno; Daniel Laheru; KATHLEEN MURPHY; Sujatha Nallapareddy; Alexis Norris-Kirby; MICHELLE RUDEK-RENAUT; Wells A Messersmith
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Investigational new drugs 2011;29(5):1057-65.
2011: A Z Burakgazi; Peter Hauer; Ahmet Hoke; Wells A Messersmith; Dhananjay Vaidya; Michael Polydefkis
Longitudinal assessment of oxaliplatin-induced neuropathy.
Neurology 2011;77(10):980-6.
2011: Chris Thompson; Stephen Leong; Wells A Messersmith
Promising targets and drugs in development for colorectal cancer.
Seminars in oncology 2011;38(4):588-97.
2011: Qing Zhou; Daniel Gustafson; Sujatha Nallapareddy; Sami Diab; Stephen Leong; Karl Lewis; Lia Gore; Wells A Messersmith; Anthony M Treston; S Gail Eckhardt; Carolyn Sidor; D Ross Camidge
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Investigational new drugs 2011;29(2):340-6.
2011: Jennifer R Diamond; Bruno R Bastos; Ryan J Hansen; Daniel L Gustafson; S Gail Eckhardt; Eunice L Kwak; Shuchi S Pandya; Graham C Fletcher; Todd M Pitts; Gillian N Kulikowski; Mark Morrow; Jamie Arnott; Mark R Bray; Carolyn Sidor; Wells A Messersmith; Geoffrey I Shapiro
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):849-60.
2011: Luis Alberto Diaz; Wells A Messersmith; Lori J Sokoll; Victoria Sinibaldi; Sandy Moore; Michael A Carducci; Mario A Eisenberger
TNF-blockade in patients with advanced hormone refractory prostate cancer.
Investigational new drugs 2011;29(1):192-4.
2011: Andrew Weickhardt; Keith Wells; Wells A Messersmith
Oxaliplatin-induced neuropathy in colorectal cancer.
Journal of oncology 2011;2011():201593.
2011: Lauren N Puls; Matthew Eadens; Wells A Messersmith
Current status of SRC inhibitors in solid tumor malignancies.
The oncologist 2011;16(5):566-78.
2011: Jeffrey R Infante; Suzanne F Jones; Johanna C Bendell; David R Spigel; Denise A Yardley; Colin D Weekes; Wells A Messersmith; John D Hainsworth; Howard A Burris
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
European journal of cancer (Oxford, England : 1990) 2011;47(2):199-205.
2010: Frank Mihlon; Charles E Ray; Wells A Messersmith
Chemotherapy agents: a primer for the interventional radiologist.
Seminars in interventional radiology 2010;27(4):384-90.
2010: Arvind Dasari; Martin D McCarter; Martine C McManus; Paul Russ; Wells A Messersmith
Recurrent pancreatic adenocarcinoma after pancreatic resection.
Oncology (Williston Park, N.Y.) 2010;24(14):1329-34.
2010: Wells A Messersmith; Antonio Jimeno; Heather A Jacene; Ming Zhao; Piotr Kulesza; Daniel Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine A Iacobuzio-Donahue; Ross C Donehower; Michael A Carducci; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Clinical colorectal cancer 2010;9(5):297-304.
2010: John J Tentler; Sujatha Nallapareddy; Aik Choon Tan; Anna Spreafico; Todd M Pitts; M Pia Morelli; Heather M Selby; Maria I Kachaeva; Sara A Flanigan; Gillian N Kulikowski; Stephen Leong; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Molecular cancer therapeutics 2010;9(12):3351-62.
2010: John J Arcaroli; Basel M Touban; Aik Choon Tan; Marileila Varella-Garcia; Rebecca W Powell; S Gail Eckhardt; Paul Elvin; Dexiang Gao; Wells A Messersmith
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(16):4165-77.
2010: Arvind Dasari; Wells A Messersmith
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(15):3811-8.
2010: JOSEPH HERMAN; Wells A Messersmith; W Warren Suh; William Blackstock; Bard C Cosman; Mohammed Mohiuddin; Matthew M Poggi; William F Regine; Leonard B Saltz; William Small; Jennifer Zook; Andre Konski
ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation.
Current problems in cancer 2010;34(3):201-10.
2010: Stephen Leong; Wells A Messersmith; Aik Choon Tan; S Gail Eckhardt
Novel agents in the treatment of metastatic colorectal cancer.
Cancer journal (Sudbury, Mass.) 2010;16(3):273-82.
2010: Wen Wee Ma; JOSEPH HERMAN; Antonio Jimeno; Daniel Laheru; Wells A Messersmith; Christopher L Wolfgang; John L Cameron; Timothy M Pawlik; Ross C Donehower; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Translational oncology 2010;3(6):373-9.
2010: Wilbur A Franklin; Jerry Haney; Michio Sugita; Lynne Bemis; Antonio Jimeno; Wells A Messersmith
KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.
The Journal of molecular diagnostics : JMD 2010;12(1):43-50.
2009: RAJESH KUMAR NV; Aik Choon Tan; Elizabeth De Oliveira; Chris Womack; Helen Wombwell; Shethah Morgan; Madhuri V Warren; Jill Walker; Tim P Green; Antonio Jimeno; Wells A Messersmith; Manuel Hidalgo
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4138-46.
2009: Wells A Messersmith; RAJESH KUMAR NV; Aik Choon Tan; Xiao Fei Wang; Veronica Diesl; Sung E Choe; Max Follettie; Christina Coughlin; Frank Boschelli; Elena Garcia-Garcia; Fernando Lopez-Rios; Antonio Jimeno; Manuel Hidalgo
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Molecular cancer therapeutics 2009;8(6):1484-93.
2009: Wen Wee Ma; Heather A Jacene; Dongweon Song; Felip Vilardell; Wells A Messersmith; Daniel Laheru; Richard L Wahl; Christopher J Endres; Antonio Jimeno; Martin G Pomper; Manuel Hidalgo
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2697-704.
2009: Antonio Jimeno; Wells A Messersmith; Fred R Hirsch; Wilbur A Franklin; S Gail Eckhardt
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
Cancer journal (Sudbury, Mass.) 2009;15(2):110-3.
2009: Antonio Jimeno; Wells A Messersmith; Fred R Hirsch; Wilbur A Franklin; S Gail Eckhardt
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(7):1130-6.
2009: S D Baker; Jaap Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; Ryan Franke; S Hu; E G Schuetz; Vishal Lamba; Wells A Messersmith; Antonio C Wolff; Michael A Carducci; Alex Sparreboom
Pharmacogenetic pathway analysis of docetaxel elimination.
Clinical pharmacology and therapeutics 2009;85(2):155-63.
2008: Antonio Jimeno; Jing Li; Wells A Messersmith; Daniel Laheru; MICHELLE RUDEK-RENAUT; Manoj Maniar; Manuel Hidalgo; Sharyn D Baker; Ross C Donehower
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5504-10.
2008: Wells A Messersmith; Antonio Jimeno; David S Ettinger; Daniel Laheru; Julie R Brahmer; Dina Lansey; Yasmin Khan; Ross C Donehower; Yusri Elsayed; Peter Zannikos; Manuel Hidalgo
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2008;63(1):181-8.
2008: Wells A Messersmith; Dennis J Ahnen
Targeting EGFR in colorectal cancer.
The New England journal of medicine 2008;359(17):1834-6.
2008: Daniel Laheru; Gary Croghan; Ronald Bukowski; MICHELLE RUDEK-RENAUT; Wells A Messersmith; Charles Erlichman; Robert Pelley; Antonio Jimeno; Ross C Donehower; Joseph Boni; Richat Abbas; Patricia Martins; Charles Zacharchuk; Manuel Hidalgo
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5602-9.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; Peter Kulesza; Wen W Ma; Jenna Wheelhouse; Anna Howard; Yasmin Khan; Ming Zhao; Heather A Jacene; Wells A Messersmith; Daniel Laheru; Ross C Donehower; Elizabeth Garrett-Mayer; Sharyn D Baker; Manuel Hidalgo
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4172-9.
2008: Hanan J Aboumater; Laura E Winner; Richard O Davis; Peter B Trovitch; Maureen M Berg; Katherina M Violette; Wells A Messersmith; Karen K Maylor; Christoph U Lehmann
No time to waste: decreasing patient wait times for chemotherapy administration using automated prioritization in an oncology pharmacy system.
The American journal of managed care 2008;14(5):309-16.
2008: Lillian L Siu; Roberto Pili; Ignacio Duran; Wells A Messersmith; Eric X Chen; Rana Sullivan; Martha Maclean; Serina King; Shirley Brown; Gregory K Reid; Zuomei Li; Ann M Kalita; Eric J Laille; Jeffrey M Besterman; Robert E Martell; Michael A Carducci
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1940-7.
2008: Antonio Jimeno; Aik Choon Tan; Jordy Coffa; RAJESH KUMAR NV; Piotr Kulesza; Belen Rubio-Viqueira; Jenna Wheelhouse; Begoña Diosdado; Wells A Messersmith; Christine A Iacobuzio-Donahue; Anirban Maitra; Marileila Varella-Garcia; Fred R Hirsch; Gerrit A Meijer; Manuel Hidalgo
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
Cancer research 2008;68(8):2841-9.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; W. PURCELL; Daniel Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2008;61(3):423-33.
2008: Antonio Jimeno; Wells A Messersmith; Carlton K K Lee; Wen W Ma; Daniel Laheru; Ross C Donehower; Sharyn D Baker; Manuel Hidalgo
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):374-9.
2007: Wells A Messersmith; Manuel Hidalgo
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4664-6.
2007: Jeffrey Crawford; Betsy Althaus; James Armitage; Lodovico Balducci; Charles L Bennett; Douglas W Blayney; Spero R Cataland; David C Dale; George D Demetri; Harry P Erba; James Foran; Alison G Freifeld; Mark L Heaney; Sally Htoy; Dwight D Kloth; Gary H Lyman; Wells A Messersmith; Laura Boehnke Michaud; Sarah C Miyata; Amy Robbins; Martin S Tallman; Saroj Vadhan-Raj; Peter Westervelt; Michael K Wong
Myeloid growth factors. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):188-202.
2007: Ming Zhao; MICHELLE RUDEK-RENAUT; Ping He; Frank-Thorsten Hafner; Martin Radtke; John J Wright; B Douglas Smith; Wells A Messersmith; Manuel Hidalgo; Sharyn D Baker
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;846(1-2):1-7.
2007: Wells A Messersmith; MICHELLE RUDEK-RENAUT; Sharyn D Baker; Ming Zhao; Connie Collins; A Dimitrios Colevas; Ross C Donehower; Michael A Carducci; Antonio C Wolff
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2007;43(1):78-86.
2006: Antonio Jimeno; Maria L Amador; Piotr Kulesza; Xiaofei Wang; Belen Rubio-Viqueira; Xiangfeng Zhang; Audrey Chan; Jenna Wheelhouse; Hidekazu Kuramochi; Koji Tanaka; Kathleen Danenberg; Wells A Messersmith; Virna Almuete; Ralph Hruban; Anirban Maitra; Charles J Yeo; Manuel Hidalgo
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Molecular cancer therapeutics 2006;5(12):3240-7.
2006: Wells A Messersmith; Manuel Hidalgo; Michael A Carducci; S Gail Eckhardt
Novel targets in solid tumors: MEK inhibitors.
Clinical advances in hematology & oncology : H&O 2006;4(11):831-6.
2006: David L Bartlett; Jordan Berlin; Gregory Y Lauwers; Wells A Messersmith; Nicholas J Petrelli; Alan P Venook
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
Annals of surgical oncology 2006;13(10):1284-92.
2006: MICHELLE RUDEK-RENAUT; Ming Zhao; Ping He; Wells A Messersmith; Sharyn D Baker
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies.
Journal of pharmaceutical and biomedical analysis 2006;42(2):253-60.
2006: Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine A Iacobuzio-Donahue; Collins A Karikari; Chanjuan Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells A Messersmith; James R Eshleman; Ralph Hruban; Anirban Maitra; Manuel Hidalgo
An in vivo platform for translational drug development in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4652-61.
2006: Jing Li; Julie R Brahmer; Wells A Messersmith; Manuel Hidalgo; Sharyn D Baker
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
Investigational new drugs 2006;24(4):291-7.
2006: Ihab R Kamel; David A Bluemke; John Eng; Eleni Liapi; Wells A Messersmith; Diane K Reyes; Jean-Francois H Geschwind
The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
Journal of vascular and interventional radiology : JVIR 2006;17(3):505-12.
2006: Wells A Messersmith; Sharyn D Baker; Lance K Lassiter; Rana A Sullivan; Kimberly Dinh; Virna I Almuete; John J Wright; Ross C Donehower; Michael A Carducci; Deborah K Armstrong
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1270-5.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Ping He; Yelena Zabelina; Runyan Jin; Wells A Messersmith; Antonio C Wolff; Sharyn D Baker
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;828(1-2):41-54.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Nicola F Smith; Robert W Robey; Ping He; Gurulingappa Hallur; Saeed R Khan; Manuel Hidalgo; Antonio Jimeno; A Dimitrios Colevas; Wells A Messersmith; Antonio C Wolff; Sharyn D Baker
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8503-11.
2005: Wells A Messersmith; Darin Oppenheimer; Josep Peralba; Valeria Sebastiani; Maria Amador; Antonio Jimeno; Erlinda Embuscado; Manuel Hidalgo; Christine A Iacobuzio-Donahue
Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis.
Cancer biology & therapy 2005;4(12):1381-6.
2004: Wells A Messersmith; Daniel Laheru; Neil Senzer; Ross C Donehower; Paula Grouleff; Theresa Rogers; Sean K Kelley; David A Ramies; Bert L Lum; Manuel Hidalgo
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6522-7.
2003: Wells A Messersmith; Daniel Laheru; Manuel Hidalgo
Recent advances in the pharmacological treatment of colorectal cancer.
Expert opinion on investigational drugs 2003;12(3):423-34.
2001: Wells A Messersmith; David F M Brown; M J Barry
The prevalence and implications of incidental findings on ED abdominal CT scans.
The American journal of emergency medicine 2001;19(6):479-81.
1997: KD Bieganowska; Lara J Ausubel; Y Modabber; E Slovik; Wells A Messersmith; David A Hafler
Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease.
The Journal of experimental medicine 1997;185(9):1585-94.
1995: J Lincoln; Wells A Messersmith
Conditions required for the measurement of nitric oxide synthase activity in a myenteric plexus/smooth muscle preparation from the rat ileum.
Journal of neuroscience methods 1995;59(2):191-7.
1995: Terrance P O'Hanlon; Wells A Messersmith; Marinos C Dalakas; Paul H Plotz; Frederick W Miller
Gamma delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies.
Clinical and experimental immunology 1995;100(3):519-28.